复发/难治性多发性骨髓瘤治疗药物的研究进展

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (595 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Multiple myeloma (MM) is a common blood system tumor characterized by the accumulation of clonal plasma cells in the bone marrow. Most MM will eventually evolve into recurrent/refractory multiple myeloma (RRMM), but for multidrug resistant RRMM patients, the efficacy of conventional cytotoxic drugs and targeted drugs are not ideal. In recent years, with the improvement of medical level and the deepening of clinical research, the clinical trial data of the new generation of original targeted drugs and new anti-MM drugs are continuously accumulated and updated, and they have shown good safety and encouraging activity, which can better relieve the symptoms of patients and prolong the survival time of patients. This review aims to collect, analyze and summarize the clinical data of iterative anti-MM targeted drugs and new anti-MM drugs, in order to understand the current development trend and provide reference for the formulation of treatment plans for RRMM patients.

Key words： Recurrent/refractory multiple myeloma Targeted drugs Combined therapy Clinical study

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	PAN Junjie1 PAN Jie2 WANG Le1▲

Cite this article:

PAN Junjie1 PAN Jie2 WANG Le1▲. Research progress of therapeutic drugs for relapsed/refractory multiple myeloma[J]. 中国当代医药, 2024, 31(1): 186-191,198.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2024/V31/I1/186

[1]	Miriyala LKV，Avasthi D.Cutaneous Multiple Myeloma[J].Cureus，2021，13（9）：17779.
[2]	Yee AJ.The role of carfilzomib in relapsed/refractory multiple myeloma[J].The Adv Hematol，2021，12：1-13.
[3]	Johnsen HE，Klausen TW，Boegsted M，et al.Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials：analysis of accrual，prognostic variables，selection bias，and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group[J].Clin Lymphoma Myeloma Leuk，2010，10（4）：290-296.
[4]	江炜，罗萍.来那度胺治疗多发性骨髓瘤的临床疗效及其安全性[J].临床合理用药杂志，2021，14（21）：30-32.
[5]	Garderet L，Kuhnowski F，Berge B，et al.Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma[J].Br J Haematol，2023，201（6）：1103-1115.
[6]	Engelhardt M，Ajayi S，Reinhardt H，et al.Pomalidomide[J].Recent Results Cancer Res，2018，212：169-185.
[7]	Mark T，Falkenstein A，Kish J.Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma[J].Future Oncol，2021，18（5）:553-564.
[8]	肖平，蔡桂程，陈文婷.长链非编码RNA H19在多发性骨髓瘤硼替佐米耐药中的作用研究[J].实验动物科学，2021， 38（5）：37-41.
[9]	张林，金晓宣，黄淑婷，等.卡非佐米及其组合药物在治疗多发性骨髓瘤的有效性及安全性分析（英文）[J].中国药学（英文版），2017，26（3）：222-229.
[10]	Fogli S，Galimberti S，Gori V，et al.Pharmacology differences among proteasome inhibitors：Implications for their use in clinical practice[J].Pharmacol Res，2021，167：105537.
[11]	王亚茹，马艳萍.伊沙佐米治疗复发难治性多发性骨髓瘤的临床疗效及安全性分析[J].临床血液学杂志，2021， 34（9）：655-659.
[12]	Spencer A，Badors A，Laubach J，et al.Phase 1，multicenter，open-label，dose-escalation，combination study（NCT02103 335）of pomalidomide（POM），marizomib（MRZ，NPI-0052），and dexamethasone（DEX）in patients with relapsed and refractory multiple myeloma（MM）；study NPI-0052-107 preliminary results[J].Cl Lymph Myelom Leuk，2015，15：e43.
[13]	Spencer A，Harrison S，Zonder J，et al.A phase 1 clinical trial evaluating marizomib，pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma（NPI-0052-107）：final study results[J].Br J Haematol，2018， 180（1）：41-51.
[14]	Selinexor for multiple myeloma[J].Aust Prescr，2022，45（6）：217-218.
[15]	李娟，侯健，蔡真，等.塞利尼索在多发性骨髓瘤临床应用的专家共识（2022）[J].临床血液学杂志，2022，35（9）：605-611.
[16]	Uddin MH，Zonder JA，Azmi AS.Exportin 1 inhibition as antiviral therapy[J].Drug Discov Today，2020，25（10）：1775- 1781.
[17]	Dimopoulos MA，Moreau P，Terpos E，et al.Multiple myeloma：EHA-ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up[J].Ann oncol，2021：32（3）：309-322.
[18]	邝丽芬，房佰俊，陈文明，等.含塞利尼索方案治疗复发难治多发性骨髓瘤的疗效与安全性分析：一项中国多中心真实世界研究[J].临床血液学杂志，2022，35（9）：626-632.
[19]	Bader JC，Abdul RAR，Shacham S，et al.Pharmacokinetics of Selinexor：The First-in-Class Selective Inhibitor of Nuclear Export.[J].Clin pharmacokinet，2021，60（8）：957-969.
[20]	陈本川.治疗复发或难治性多发性骨髓瘤新药——塞利尼索（selinexor）[J].医药导报，2020，39（2）：268-275.
[21]	Shahin R，Aljamal S.Kinesin spindle protein inhibitors in cancer：from high throughput screening to novel therapeutic strategies[J].Future Sci OA，2022，8（3）：FSO778.
[22]	林扬，杨宇豪，蒋启凌，等.驱动蛋白Eg5的抑制剂及其抗肿瘤作用机制[J].福建医科大学学报，2022，56（1）：88-93.
[23]	Azmi AS，Uddin MH，Mohammad RM.The nuclear export protein XPO1 - from biology to targeted therap[J].Nat Rev Clin Oncol，2021，18（3）：152-169.
[24]	Pan D，Kaufman JL，Htut M，et al.Filanesib plus bortezomib and dexamethasone in relapsed/refractory t（11；14）and 1q21 gain multiple myeloma[J].Cancer Med，2021，11（2）：358- 370.
[25]	Kumar SK，Laplant B，Chng WJ，et al.Dinaciclib，a novel CDK inhibitor，demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma[J].Blood，2015，125（3）：443-448.
[26]	Tang HL，Xu L，Liang X，et al.Low dose dinaciclib enhances doxorubicin-induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways[J].Oncol Lett，2018，16（5）：6608-6614.
[27]	Ehsan H，Wahab A，Shah Z，et al.Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma[J].J Hematol，2021，10（3）：89-97.
[28]	杨璐，游静茹，陈雅洁，等.BCL-2抑制剂维奈托克在血液系统恶性肿瘤治疗中的应用研究进展[J].山东医药，2022，62（29）：103-107.
[29]	Regidor B，Goldwater MS，Wang J，et al.Low dose venetoclax in combination with bortezomib，daratumumab，and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study[J].Ann Hematol，2021，100（8）：2061-2070.
[30]	Kaufman JL，Gasparetto C，Schjesvold FH，et al.Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t（11；14）multiple myeloma[J].Am J Hematol，2021，96（4）：418-427.
[31]	Von SM，Sultana KN，Elbezanti WO，et al.Bruton's Tyrosine Kinase Targeting in Multiple Myeloma[J].Int J Mol Sci，2021， 22（11）：5707.
[32]	Ailawadhi S，Parrondo RD，Moustafa MA，et al.Ibrutinib，lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma：Phase I trial results[J].Hematol Oncol，2022，40（4）：695-703.
[33]	宋敏，张子雨，张宏伟，等.基于FAERS数据库的伊布替尼不良事件信号挖掘研究[J].肿瘤药学，2021，11（4）：406-412.
[34]	Petruccim T，Vozella F.The Anti-CD38 antibody therapy in multiple myeloma[J].Cells，2019，8（12）：1629.
[35]	贺玉钦，陈文明.达雷妥尤单抗在多发性骨髓瘤中的应用[J].临床血液学杂志，2023，36（7）：461-467.
[36]	郭军.达雷妥尤单抗在复发难治性多发性骨髓瘤的应用价值分析[J].中国临床药理学与治疗学，2023，28（5）：602.
[37]	严晓琴，余娟，邹夏，等.达雷妥尤单抗治疗复发难治性多发性骨髓瘤疗效及对患者骨髓液CD38水平的影响[J].西部医学，2021，33（10）：1482-1485，1491.
[38]	Granger K，Gaffney KJ，Davis JA.Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma[J].Oncol Pharm Pract.2023，29（3）：722-726.
[39]	Touzeau C，Krishnan AY，Moreau P，et al.Efficacy and safety of teclistamab（tec），a B-cell maturation antigen（BCMA）×CD3 bispecific antibody，inpatients（pts）with relapsed/refractory multiple myeloma（RRMM）after exposure to other BCMA-targeted agents[J].Clin Oncol，2022，40：8013.
[40]	Moreau P，Garfall AL，van de Donk NWCJ，et al.Teclistamab in Relapsed or Refractory Multiple Myeloma[J]N Engl J Med，2022，387（6）：495-505.
[41]	Munshi NC，Anderson LD，Shah N，et al.Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma[J].N Engl J Med，2021，384（8）：705-716.
[42]	夏训明.美国FDA批准首种用于治疗多发性骨髓瘤基因疗法药物Abecma（idecabtagene vicleucel）[J].广东药科大学学报，2021，37（3）：29.
[43]	Anderson LD.Idecabtagene vicleucel（ide-cel）CAR T-cell therapy for relapsed and refractory multiple myeloma[J].Future Oncol，2021，18（3）：277-289.